Rapport Therapeutics (RAPP) Cash & Equivalents (2023 - 2026)
Rapport Therapeutics (RAPP) posted quarterly Cash & Equivalents of $78.1 million for Q1 2026, up 35.5% year-over-year from $57.6 million in Q1 2025, and up 48.27% quarter-over-quarter from $52.6 million in Q4 2025.
Rapport Therapeutics (RAPP) Cash & Equivalents (2023 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has reported Cash & Equivalents for 4 consecutive years, with $78.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Equivalents rose 35.5% year-over-year to $78.1 million; the TTM figure through Mar 2026 stood at $78.1 million (up 35.5% YoY), while the FY2025 annual figure was $52.6 million, down 7.32% from the prior year.
- Cash & Equivalents improved to $78.1 million in Q1 2026 per RAPP's latest filing, from $52.6 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $513.0 million in Q3 2025 and bottomed at $39.3 million in Q3 2024.
- Historically, Cash & Equivalents has averaged $129.3 million across 4 years, with a median of $76.2 million in 2024.
- Annual changes were most pronounced in 2024 — Cash & Equivalents tumbled 75.34% — and 2025, when it jumped 1204.88%.
- Rapport Therapeutics' Cash & Equivalents stood at $70.2 million in 2023, then fell by 19.05% to $56.8 million in 2024, then slipped by 7.32% to $52.6 million in 2025, then soared by 48.27% to $78.1 million in 2026.
- Business Quant data shows RAPP's Cash & Equivalents at $78.1 million in Q1 2026, $52.6 million in Q4 2025, and $513.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Rapport Therapeutics | 2.27 Bn | 2.27 Bn | - | 63.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 63.61 Mn |
| Mar 31, 2026 | 78.06 Mn |
| Dec 31, 2025 | 52.65 Mn |
| Sep 30, 2025 | 513.00 Mn |
| Jun 30, 2025 | 260.40 Mn |
| Mar 31, 2025 | 57.60 Mn |
| Dec 31, 2024 | 56.81 Mn |
| Sep 30, 2024 | 39.31 Mn |
| Jun 30, 2024 | 110.16 Mn |
| Mar 31, 2024 | 74.27 Mn |
| Dec 31, 2023 | 70.17 Mn |
| Sep 30, 2023 | 159.41 Mn |
| Jun 30, 2023 | 79.53 Mn |